Posted on October 11, 2016 by Sitemaster
In August we had reported on an announcement by OncoGenex Pharmaceuticals that, in the Phase III AFFINITY trial, the combination of custirsen + cabazitaxel (Jevtana) + prednisone had no significant impact on overall survival of men with metastatic, castration-resistant prostate cancer (mCRPC) who had already received first-line chemotherapy by comparison with cabazitaxel + prednisone alone. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: AFFINITY, cabazitaxel, custirsen, outcome, Phase III, trial | Leave a comment »
Posted on August 16, 2016 by Sitemaster
Early this morning, OncoGenex announced the result of final analysis of data from the Phase III AFFINITY trial of custirsen + cabazitaxel + prednisone in men with metastatic, castration-resistant prostate cancer (mCRPC) who had progressed after docetaxel chemotherapy. … READ MORE …
Filed under: Drugs in development | Tagged: castration-resistant, custirsen, mCRPC, metastatic, OncoGenex | Leave a comment »
Posted on April 28, 2014 by Sitemaster
OncoGenex and Teva stated earlier today that the addition of custirsen (OGX-011) to docetaxel + prednisone did not demonstrate any significant effect on the overall survival of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: castration-resistant, custirsen, mCRPC, metastatic, OGX-011 | Leave a comment »
Posted on April 23, 2014 by Sitemaster
According to a media release from OncoGenex, the U.S. Food & Drug Administration has granted a “fast track” designation to the evaluation of data from the so-called AFFINITY trial of custiren + carbazitaxel + prednisone as a second-line treatment for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: AFFINITY, castration-resistant, custirsen, mCRPC, metastatic, OGX-011 | 2 Comments »
Posted on February 11, 2014 by Sitemaster
According to a media release issued early this morning by OncoGenex Pharmaceuticals, the Phase III SYNERGY trial of custirsen (originally known as OGX-011) has reached its pre-specified endpoint in terms of the number of events required for final analysis of the trial data. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, custirsen, mCRPC, metastatic, OGX-011, outcome, trial | 1 Comment »
Posted on November 19, 2013 by Sitemaster
According to a media release issued by OncoGenex Pharmaceuticals earlier today, the Phase III SYNERGY trial of docetaxel + prednisone + custirsen vs. docetaxel + prednisone + a placebo will be “continuing as planned per the recommendation of the Independent Data Monitoring Committee (IDMC).” … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, chemotherapy, custirsen, mCRPC, metastatic, OGX-011 | Leave a comment »
Posted on November 6, 2012 by Sitemaster
Well, it’s taken a little over 2 years, but OncoGenex has completed enrollment of patients into the randomized, double-blind, Phase III SYNERGY trial, which is designed to assess whether the addition of custirsen (OGX-011) to docetaxel-based chemotherapy can extend the survival of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development | Tagged: custirsen, mCRPC, OGX-011, Phase III, trial | 6 Comments »
Posted on August 7, 2012 by Sitemaster
According to a media release from OncoGenex Pharmaceuticals earlier today, the company has started to enroll patients in a second, randomized, Phase III clinical trial of custirsen (OGX-011), this time in combination with second-line chemotherapy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, castration-resistant, chemotherapy, custirsen, metastatic, OGX-011, second-line | Leave a comment »
Posted on March 9, 2012 by Sitemaster
According to a media release from the companies issued yesterday, OncoGeneX and Teva have stopped enrolling patients into the SATURN trial, which was designed to see if OGX-011 (custirsen) could ameliorate bone pain … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: cabazitaxel, castration-resistant, custirsen, metastatic, OGX-011 | Leave a comment »
Posted on September 19, 2011 by Sitemaster
The Phase III SATURN clinical trial of OGX-011 in treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) after initial chemotherapy with docetaxel + prednisone required men to be randomized to either docetaxel + prednisone + OGX-011 or to docetaxel + prednisone + a placebo. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, custirsen, docetaxel, OGX-011, pain, SATURN, survival, synergy | Leave a comment »
Posted on September 14, 2010 by Sitemaster
Back in 2009 we reported the results of a randomized Phase II trial of docetaxel + OGX-011 vs. docetaxel + placebo as they were initially presented at the annual meeting of the American Society of Clinical Oncology in Chicago (ASCO). … READ MORE …
Filed under: Drugs in development | Tagged: CRPC, custirsen, OGX-011 | Leave a comment »
Posted on June 21, 2010 by Sitemaster
OncoGenex has initiated the first of two Phase III trials of custirsen sodium (OGX-011) in the treatment of men with metastatic castrate-resistant prostate cancer (mCPRC). … READ MORE …
Filed under: Drugs in development, Uncategorized | Tagged: castration-resistant, custirsen, mCRPC, OGX-011, OncoGenex | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 